Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U
    Session Type: B2B

    Breakfast Symposium: Innovative Technologies Transforming Bladder Cancer Care

    Saturday, November 1, 2025
    08:00 - 08:45 GMT+0

    Bench-to-Bedside SIU@U

    This symposium is supported by B2B Presenting Sponsor Johnson & Johnson.

      Chair(s)

    • Peter Black

      Professor
      University of British Columbia, Canada

    Learning Objectives :

    At the end of this session, attendees should be able to:
    • Evaluate the evolving role of primary ablation therapies for intermediate-risk NMIBC, along with their implications for the current standard of care.
    • Assess novel intravesical approaches for high-risk NMIBC treatment and their influence on treatment decision-making.
    • Examine the clinical evidence associated with novel intravesical therapies for the management of MIBC and their practical implications for patient care.

    Presentations:

    • 08:00 - 08:05 GMT+0
      Welcome and Introductions

      Chair: Peter Black – University of British Columbia

    • 08:05 - 08:15 GMT+0
      Primary Ablation of Intermediate-Risk NMIBC: A Paradigm Shift?

      Speaker: Gautier Marcq – Lille University

    • 08:15 - 08:25 GMT+0
      Redefining Treatment for High-Risk NMIBC Through Innovative Technologies

      Speaker: Sarah P. Psutka – University of Washington

    • 08:25 - 08:35 GMT+0
      Intravesical Therapy for Muscle-Invasive Bladder Cancer: Innovation or Illusion?

      Speaker: Kilian Martin Gust – Austria

    • 08:35 - 08:45 GMT+0
      Panel Discussion and Q&A

      Moderator: Peter Black – University of British Columbia

      Panelist: Gautier Marcq – Lille University

      Panelist: Sarah P. Psutka – University of Washington

      Panelist: Kilian Martin Gust – Austria